Browsing by Author "Ayinde T.O."

Now showing 1 - 3 of 3
  • Item
    A new model for alloxan-induced diabetes mellitus in rats
    (Bangladesh Society of Physiologists, 2019) Ojulari L.S.; Oladeru O.O.; Ayinde T.O.; Kadir R.E.; Dangana O.E.; Alade I.O.
    Background:Alloxan is widely used to induce experimental diabetes mellitus (DM) in animals with different grades of disease severity by varying the dose of Alloxan used. This method has however be questioned by recent research work as an appropriate technique for the induction of diabetes. Objective: To provide a simple, yet concise and reproducible experimental procedure and model for Alloxan-induced DM in rats. Methods: The study was divided into 2 separate experiments. Experiment 1: Alloxan was administered, into four subgroups each (group 1- 100 mg of Alloxan /kg of rat body weight, group 2- 120 mg/kg, group 3- 150 mg/kg, and group 4- 170 mg/kg); in each subgroup, the dose of Alloxan was administered at different concentrations (20 mg/ml, 10 mg/ml, 5 mg/ml and 4 mg/ml) in groups of 10 rats each. The pre-induction fasting period was also varied between groups. Experiment 2:Following a pre-induction fasting period of 36 hours, animals received 150 mg Alloxan /kg body weight and at a concentration of 20 mg Alloxan/ ml. Result:Alloxan administered intraperitoneally at 150 mg/kg of rat body weight, at 20 mg/ml and following a pre-induction fast period of 36 hours yielded the most favorably conditions with the least recorded mortality. Conclusion: From the results of this study, it can be concluded that alloxan is a diabetogenic drug with a strict protocol of use in inducing a predictable DM in rats and as such, this model is a standard and reproducible technique for the induction of DM in experimental rats.
  • Item
    Comparative Analysis of Handgrip Strength and Urine C-Peptide Creatinine Ratio as Biomarkers for Glucose Regulation in Young Adult Females in the University of Ilorin: A Cross-Sectional Study
    (Nigerian Society for Experimental Biology, 2023) Ojulari L.S.; Sulaiman S.E.; Ayinde T.O.; Kadir E.R.; Jimoh-Abdulghaffaar H.O.; Sulaiman H.
    Handgrip strength (HGS) is a robust biomarker predicting future disability, metabolic syndrome, and diabetes. Urinary C-peptide creatinine ratio (UCPCR) emerges as a novel, non-invasive tool under exploration for assessing beta cell function and glucose regulation. Despite their significance in gauging muscle strength, mass, and overall metabolic function, gaps remain in understanding the full extent of handgrip strength and UCPCR's efficiency. This study aimed to identify a better biomarker for glucose regulation by studying the relationship between handgrip strength, urine c-peptide creatinine ratio, and blood glucose levels in adult females. Using ELISA, the study measured handgrip strength, blood glucose levels, and urine samples. Social demographic data was obtained through standard questionnaires, and statistical analysis was done using IBM 25 SPSS software with Pearson's correlation, linear regression at P=< 0.05, and T-test. The study found that handgrip strength (HGS) had a slight non-significant positive correlation with fasting blood sugar (FBS) (P=0.386). However, there was a significant correlation between HGS and 2 hours postprandial glucose (2HPG) in both dominant and non-dominant hands (P= 0.045 vs P= 0.017). Additionally, the study found that handgrip strength in the dominant hand was significantly stronger than that in the non-dominant hand (P= 0.001). On the other hand, the urinary C-peptide creatinine ratio (UCPCR) had no significant correlations with FBS and 2HPG. Handgrip strength measurements provide an indicative approach for glucose regulation and are a better biomarker for blood glucose regulation than UCPCR
  • Item
    Evaluating the hypoglycaemic, anti-inflammatory, and antioxidant effects of Hibiscus sabdariffa in alloxan-induced diabetic rats
    (I. Horbachevsky Ternopil National Medical University, Ukraine, 2025) Ojulari L.S.; Njinga N.S.; Ganiyu R.A.; Ayinde T.O.; Kadir E.R.
    Hibiscus sabdariffa is beneficial in treating diabetes mellitus. This study investigated the hypoglycaemic, antiinflammatory, and antioxidant effects of Hibiscus sabdariffa in alloxan-induced diabetic rats. Thirty Wistar rats were divided into six groups of five and acclimatised for two weeks before the experiment commenced. Group I: non-diabetic control; Group II: diabetic control; Group III: non-diabetic with 200 mg/kg of Hibiscus sabdariffa; Group IV: non-diabetes with 300 mg/kg of Hibiscus sabdariffa; Group V: diabetic with 200 mg/kg of Hibiscus sabdariffa; Group VI: diabetic with 300 mg/kg of Hibiscus sabdariffa. The rats received a single intraperitoneal injection of alloxan (150 mg/kg of body weight), and diabetic rats were treated with Hibiscus sabdariffa for 21 days. Fasting blood glucose levels, insulin levels, superoxide dismutase, catalase, malondialdehyde, interleukin-6, and tumour necrosis factor-alpha were measured, and organ and blood samples were collected. The results were analysed using analysis of variance with p < 0.05 considered significant, and data were visualised using GraphPad. This study demonstrated that Hibiscus sabdariffa exerts significant effects on diabetic parameters, pro-inflammatory cytokines, and antioxidant enzymes. Daily oral treatment for 21 days lowered fasting blood glucose, interleukin-6, tumour necrosis factor-alpha, and malondialdehyde levels. It also enhanced insulin production, superoxide di smutase, and catalase activity in the skeletal muscle, liver, pancreas, and kidney. It can be concluded that Hibiscus sabdariffa is beneficial in treating diabetes mellitus. This study investigated the hypoglycaemic, antiinflammatory, and antioxidant effects of Hibiscus sabdariffa in alloxan-induced diabetic rats. Thirty Wistar rats were divided into six groups of five and acclimatised for two weeks before the experiment commenced. Group I: non-diabetic control; Group II: diabetic control; Group III: non-diabetic with 200 mg/kg of Hibiscus sabdariffa; Group IV: non-diabetes with 300 mg/kg of Hibiscus sabdariffa; Group V: diabetic with 200 mg/kg of Hibiscus sabdariffa; Group VI: diabetic with 300 mg/kg of Hibiscus sabdariffa. The rats received a single intraperitoneal injection of alloxan (150 mg/kg of body weight), and diabetic rats were treated with Hibiscus sabdariffa for 21 days. Fasting blood glucose levels, insulin levels, superoxide dismutase, catalase, malondialdehyde, interleukin-6, and tumour necrosis factor-alpha were measured, and organ and blood samples were collected. The results were analysed using analysis of variance with p < 0.05 considered significant, and data were visualised using GraphPad. This study demonstrated that Hibiscus sabdariffa exerts significant effects on diabetic parameters, pro-inflammatory cytokines, and antioxidant enzymes. Daily oral treatment for 21 days lowered fasting blood glucose, interleukin-6, tumour necrosis factor-alpha, and malondialdehyde levels. It also enhanced insulin production, superoxide di smutase, and catalase activity in the skeletal muscle, liver, pancreas, and kidney. It can be concluded that Hibiscus sabdariffa is beneficial in treating diabetes mellitus. This study investigated the hypoglycaemic, antiinflammatory, and antioxidant effects of Hibiscus sabdariffa in alloxan-induced diabetic rats. Thirty Wistar rats were divided into six groups of five and acclimatised for two weeks before the experiment commenced. Group I: non-diabetic control; Group II: diabetic control; Group III: non-diabetic with 200 mg/kg of Hibiscus sabdariffa; Group IV: non-diabetes with 300 mg/kg of Hibiscus sabdariffa; Group V: diabetic with 200 mg/kg of Hibiscus sabdariffa; Group VI: diabetic with 300 mg/kg of Hibiscus sabdariffa. The rats received a single intraperitoneal injection of alloxan (150 mg/kg of body weight), and diabetic rats were treated with Hibiscus sabdariffa for 21 days. Fasting blood glucose levels, insulin levels, superoxide dismutase, catalase, malondialdehyde, interleukin-6, and tumour necrosis factor-alpha were measured, and organ and blood samples were collected. The results were analysed using analysis of variance with p < 0.05 considered significant, and data were visualised using GraphPad. This study demonstrated that Hibiscus sabdariffa exerts significant effects on diabetic parameters, pro-inflammatory cytokines, and antioxidant enzymes. Daily oral treatment for 21 days lowered fasting blood glucose, interleukin-6, tumour necrosis factor-alpha, and malondialdehyde levels. It also enhanced insulin production, superoxide di smutase, and catalase activity in the skeletal muscle, liver, pancreas, and kidney. It can be concluded that Hibiscus sabdariffa is beneficial in treating diabetes mellitus. This study investigated the hypoglycaemic, antiinflammatory, and antioxidant effects of Hibiscus sabdariffa in alloxan-induced diabetic rats. Thirty Wistar rats were divided into six groups of five and acclimatised for two weeks before the experiment commenced. Group I: non-diabetic control; Group II: diabetic control; Group III: non-diabetic with 200 mg/kg of Hibiscus sabdariffa; Group IV: non-diabetes with 300 mg/kg of Hibiscus sabdariffa; Group V: diabetic with 200 mg/kg of Hibiscus sabdariffa; Group VI: diabetic with 300 mg/kg of Hibiscus sabdariffa. The rats received a single intraperitoneal injection of alloxan (150 mg/kg of body weight), and diabetic rats were treated with Hibiscus sabdariffa for 21 days. Fasting blood glucose levels, insulin levels, superoxide dismutase, catalase, malondialdehyde, interleukin-6, and tumour necrosis factor-alpha were measured, and organ and blood samples were collected. The results were analysed using analysis of variance with p < 0.05 considered significant, and data were visualised using GraphPad. This study demonstrated that Hibiscus sabdariffa exerts significant effects on diabetic parameters, pro-inflammatory cytokines, and antioxidant enzymes. Daily oral treatment for 21 days lowered fasting blood glucose, interleukin-6, tumour necrosis factor-alpha, and malondialdehyde levels. It also enhanced insulin production, superoxide di smutase, and catalase activity in the skeletal muscle, liver, pancreas, and kidney. It can be concluded that Hibiscus sabdariffa has the potential to manage hyperglycaemia and inflammation while improving antioxidant enzyme activity. Furthermore, it may serve as a natural source or agent for the treatment or prevention of diabetes